Entendiendo las terapias actuales en melanoma metastásico / Understanding current therapies in metastatic melanoma
Rev. méd. Chile
; 144(11): 1448-1458, nov. 2016. ilus, tab
Article
in Spanish
| LILACS
| ID: biblio-845467
Responsible library:
CL1.1
ABSTRACT
Cutaneous melanoma is a highly aggressive tumor developing from melanocytes, its incidence is increasing, and prognosis in advanced stages is daunting. New therapies have been approved during the recent years with unprecedented results, including inhibitors of MAPK/ERK pathway and immune checkpoint blockade (anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) as ipilimumab, anti-programmed cell death protein 1 (PD-L1) as pembrolizumab and anti-programmed cell death protein 1 ligand (PD-L1), among many others). The aim of this paper is to review currently available metastatic melanoma therapies focusing mainly on new therapies that have demonstrated effectiveness, after several decades of little progress in the treatment of this disease.
Full text:
Available
Collection:
International databases
Database:
LILACS
Main subject:
Skin Neoplasms
/
Melanoma
/
Antineoplastic Agents
Limits:
Humans
Language:
Spanish
Journal:
Rev. méd. Chile
Journal subject:
Medicine
Year:
2016
Document type:
Article
Affiliation country:
Chile
Institution/Affiliation country:
Pontificia Universidad Católica de Chile/CL